Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.4046
-0.0248-5.78%
Volume:1.58M
Turnover:643.38K
Market Cap:29.74M
PE:-0.23
High:0.4288
Open:0.4197
Low:0.3950
Close:0.4294
52wk High:3.39
52wk Low:0.3801
Shares:73.51M
Float Shares:58.18M
Volume Ratio:1.32
T/O Rate:2.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7940
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-176.82%
PB:-0.92
PE(LYR):-0.23

Loading ...

Outlook Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Jan 27

Press Release: Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Dow Jones
·
Jan 06

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires Live
·
Jan 03

Crude Oil Falls 1%; US Manufacturing Growth Eases In December

Benzinga
·
Jan 03

BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Tesla, MGM Resorts

Reuters
·
Jan 02

Top Premarket Decliners

MT Newswires Live
·
Jan 02

BUZZ-U.S. STOCKS ON THE MOVE-Silver and gold miners, Baidu, Outlook Therapeutics

Reuters
·
Jan 02

BUZZ-Outlook Therapeutics plunges after FDA rejects eye drug for third time

Reuters
·
Jan 02

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus

Benzinga
·
Jan 02

Outlook Therapeutics Shares Plunge 61.5% Premarket After US FDA Declines to Approve Eye Disease Drug

THOMSON REUTERS
·
Jan 02

Stocks to Watch: Nuvve, Outlook Therapeutics, Rubico

Dow Jones
·
Jan 01

BRIEF-Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava

Reuters
·
Jan 01

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

Dow Jones
·
Jan 01

Outlook Therapeutics Says FDA Issued Complete Response Letter to ONS-5010 BLA Resubmission

MT Newswires Live
·
Jan 01

US FDA declines to approve Outlook Therapeutics' eye disease drug

Reuters
·
Jan 01

Outlook Therapeutics Inc - FDA Issues Complete Response Letter for Ons-5010 Bla

THOMSON REUTERS
·
Jan 01

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd

THOMSON REUTERS
·
Jan 01

Outlook Therapeutics Inc: Currently Exploring All Available Pathways for Potential Approval in U.s

THOMSON REUTERS
·
Jan 01

Outlook Therapeutics Inc: FDA Has Not Indicated What Type of Confirmatory Evidence Would Be Acceptable

THOMSON REUTERS
·
Jan 01

NASDAQ TRADE HALT HALT NEWS PENDING AT 04:10 PM

Reuters
·
Jan 01